经非人灵长类筛选获得的AAV变体可高效转导脑组织并驱动非人灵长类和小鼠分泌蛋白表达
研究在成年非人灵长类脑室内注射数百万个肽修饰的AAV1、AAV2和AAV9衣壳变体进行体内筛选,获得AAV-Ep+衣壳,其在非人灵长类室管膜细胞和大脑神经元转导效力显著提高,并在三种非人灵长类、两种小鼠品系及人诱导多能干细胞来源神经元中保守。用AAV-Ep+包装人TPP1转基因经脑室内注射TPP1活性缺失小鼠,提供稳健且治疗相关的TPP1蛋白浓度,显著改善震颤和寿命;非人灵长类脑室内给药总剂量1×10^12病毒基因组后脑脊液TPP1浓度高,剂量比先前报道的非人灵长类剂量低30倍以上。
要点
- AAV-Ep+在非人灵长类室管膜细胞和大脑神经元中转导效力显著提高。
- AAV-Ep+效力在三种非人灵长类、两种小鼠品系及人诱导多能干细胞来源神经元中保守。
- 非人灵长类脑室内注射AAV-Ep+.hTPP1总剂量1×10^12病毒基因组后脑脊液TPP1浓度高,比先前报道剂量低30倍以上。
核心结论
- 结果表明AAV-Ep+可能是需要脑脊液蛋白表达时基因治疗应用的有力载体。
研究设计与样本
- 在成年非人灵长类中脑室内注射数百万个肽修饰的AAV1、AAV2和AAV9亲本血清型衣壳变体进行体内筛选,以鉴定脑室内注射后高效转导关键脑组织(包括室管膜)的衣壳。
主要发现
- AAV-Ep+在非人灵长类室管膜细胞和大脑神经元中转导效力显著提高,且效力在三种非人灵长类、两种小鼠品系及人诱导多能干细胞来源神经元中保守。
- 在TPP1活性缺失小鼠中,AAV-Ep+.hTPP1经脑室内注射提供稳健且治疗相关的TPP1蛋白浓度,显著改善震颤和寿命。
- 非人灵长类脑室内注射AAV-Ep+.hTPP1总剂量1×10^12病毒基因组后脑脊液TPP1浓度高,该剂量比先前报道的非人灵长类剂量低30倍以上。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent work has shown that prolonged expression of recombinant proteins after adeno-associated virus (AAV)-mediated delivery of gene therapy to long-lived, ventricle-lining ependymal cells can profoundly affect disease phenotypes in animal models of neurodegenerative diseases. Here, we performed in vivo screens of millions of peptide-modified capsid variants of AAV1, AAV2, and AAV9 parental serotypes in adult nonhuman primates (NHPs) to identify capsids with potent transduction of key brain tissues, including ependyma, after intracerebroventricular injection. Through these screens, we identified an AAV capsid, AAV-Ep+, with markedly increased potency in transducing ependymal cells and cerebral neurons in NHPs. AAV-Ep+'s potency was conserved in three species of NHP, two mouse strains, and human neurons derived from induced pluripotent stem cells. To apply AAV-Ep+ to the treatment of ceroid lipofuscinosis type 2 disease, a lysosomal storage disorder caused by loss-of-function mutations in tripeptidyl-peptidase 1 (TPP1), we used the capsid to package the human TPP1 transgene (AAV-Ep+.hTPP1) and delivered the construct by intracerebroventricular injection into mice lacking TPP1 activity. AAV-Ep+ provided robust and therapeutically relevant TPP1 protein concentrations in these mice, significantly improving tremor and life span. In NHPs, high cerebrospinal fluid (CSF) TPP1 concentrations were achieved after intracerebroventricular delivery of AAV-Ep+.hTPP1 at a total dose of 1 × 1012 viral genomes, which was more than 30× lower than previously reported doses in NHPs. These results suggest that AAV-Ep+ may be a potent vector for gene therapy applications where CSF protein expression is required.
引用
- Tecedor L, Chen YH, Leib DE, et al. An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice. Sci Transl Med. 2025. PMID: 40367194. doi:10.1126/scitranslmed.adr2531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。